What Was Approved?
The U.S. Food and Drug Administration approved Lipfendra (enlicitide) as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol, or LDL-C, in adults with hypercholesterolemia, including adults with heterozygous familial hypercholesterolemia (HeFH).
Lipfendra is notable because it is the first oral medication approved to inhibit PCSK9. Previous PCSK9 inhibitors have been available as injectable treatments.
What Is LDL Cholesterol?
LDL cholesterol is often called “bad” cholesterol because high levels can contribute to plaque buildup inside arteries.
Over time, this buildup may narrow blood vessels and increase the risk of cardiovascular problems such as heart attack and stroke.
High cholesterol often does not cause noticeable symptoms, so it is typically detected through blood testing.
What Is Heterozygous Familial Hypercholesterolemia?
Heterozygous familial hypercholesterolemia, or HeFH, is an inherited condition that can cause unusually high LDL cholesterol levels.
People with HeFH may require medication in addition to diet, exercise, and other lifestyle measures to help control LDL-C.
How Does Lipfendra Work?
Lipfendra inhibits proprotein convertase subtilisin/kexin type 9, or PCSK9.
PCSK9 affects the number of LDL receptors available on liver cells.
Blocking PCSK9 allows more LDL receptors to remain available to help remove LDL cholesterol from the bloodstream.
How Is Lipfendra Taken?
According to the FDA, Lipfendra is an oral tablet taken once daily.
Patients should follow the exact dosing and administration instructions in the FDA-approved prescribing information.
It is intended to be used together with appropriate diet and exercise rather than as a replacement for those measures.
What Did the Clinical Trials Show?
The FDA evaluated Lipfendra in two randomized, double-blind, placebo-controlled clinical trials involving a total of 3,207 adults with hypercholesterolemia who were receiving maximally tolerated statin therapy.
The primary outcome in both studies was the percentage change in LDL-C from baseline to Week 24.
In one study involving adults with established atherosclerotic cardiovascular disease or a high risk for it, Lipfendra produced an average 56% reduction in LDL-C compared with placebo at Week 24.
In the study involving adults with HeFH, the average reduction was 59% compared with placebo.
What Are the Common Side Effects?
In one of the clinical trials, the overall frequency of adverse reactions was similar between Lipfendra and placebo.
In the HeFH study, adverse reactions reported more often with Lipfendra than placebo included:
- Diarrhea
- Dizziness
Not every patient will experience these effects, and the complete safety information should be reviewed before treatment.
Does Lipfendra Replace Statins?
Not necessarily.
In the studies supporting approval, patients were already receiving maximally tolerated statin therapy.
Treatment choices depend on factors such as:
- Current LDL-C level
- Cardiovascular risk
- Response to current therapy
- Statin tolerance
- Other medical conditions
- Other medications
A healthcare professional should determine how Lipfendra fits into an individual treatment plan.
Does Lipfendra Prevent Heart Attacks or Strokes?
The approved indication is specifically for lowering LDL-C.
Although lowering LDL-C is an established part of cardiovascular risk reduction, patients should not assume that a specific degree of LDL lowering guarantees prevention of a heart attack or stroke.
Treatment decisions should be based on the patient’s overall cardiovascular risk and medical history.
Why Is This Approval Important?
PCSK9 inhibition has been an important strategy for lowering LDL cholesterol, but previously approved PCSK9 inhibitors have primarily been injectable treatments.
Lipfendra provides the first FDA-approved oral PCSK9 inhibitor, giving clinicians another option for adults who need additional LDL-C reduction.
FDA also lists Lipfendra among its 2026 novel drug approvals.
Bottom Line
Lipfendra (enlicitide) is the first FDA-approved oral PCSK9 inhibitor.
It is approved as an adjunct to diet and exercise to lower LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
Clinical trials showed substantial LDL-C reductions at 24 weeks, but treatment should still be individualized based on cardiovascular risk, current therapy, medical history, and treatment goals.
Sources
- U.S. Food and Drug Administration (FDA) — FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol, July 2026.
- U.S. Food and Drug Administration (FDA) — Lipfendra (enlicitide) Approval Letter, NDA 220848.
- U.S. Food and Drug Administration (FDA) — Novel Drug Approvals for 2026.